Clinical Trial Update: A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD. [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of a single-dose and multi-dose HRS-9821 inhalation in healthy subjects and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• HRS-9821 powder for inhalation

Snippet

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Conditions: COPD | Phase 1 | Status: RECRUITING